Key result
A booster dose of the Japanese encephalitis chimeric vaccine given 12-24 months after primary immunization resulted in a 100% seroprotection rate and a >50-fold increase in geometric mean titer.
Why the study?
Does a JE-CV booster given 12-24 months after primary vaccination improve immunogenicity and maintain safety in healthy children?
Does a JE-CV booster given 12-24 months after primary vaccination improve immunogenicity and maintain safety in healthy children?
A JE-CV booster given 12-24 months after primary vaccination in children is highly immunogenic and safe.
Answers are grounded in this paper and cite their sources.
Supports JE-CV booster immunogenicity in children; leaves open randomized confirmation of durability and optimal timing.
BACKGROUND: This study evaluated the effect of a booster vaccination of a new, live attenuated, Japanese encephalitis chimeric vaccine (JE-CV). Previously this vaccine has been used as a booster 12 months after priming with an inactivated vaccine and at >24 months after priming with the same JE-CV. This study evaluates the immunogenicity and safety of the JE-CV given at 12-24 months after JE-CV priming. METHODS: Phase III, open-label study in the Republic of Korea in which 119 children previously vaccinated with JE-CV at 12-24 months of age received a JE-CV booster at 12-24 months after primary vaccination. JE neutralizing antibody titers were measured using >50% plaque reduction neutralization test prebooster and 1 month postbooster vaccination. Seroprotection (SP) was defined as ≥10 (1/dil). Safety was assessed for 28 days postvaccination by parental reports. Serious adverse events were monitored for 6 months postvaccination. RESULTS: Antibody persistence was high prebooster (SP rate 93.5%). There was a strong anamnestic response postbooster vaccination, with an SP rate of 100% and a >50-fold increase in geometric mean titer from the prebooster level. Both antibody persistence and the booster response were independent of whether the booster was given at 12-17 or 18-24 months. The safety profile was good and comparable with the primary vaccination; there were no vaccine-related serious adverse events and no deaths. CONCLUSIONS: This study confirms the suitability of a JE-CV booster vaccination at 12-24 months after a primary dose of the same vaccine given at 12-24 months of age in children in the Republic of Korea.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2015) studied Healthy children previously vaccinated with JE-CV (n=119). Japanese encephalitis chimeric vaccine (JE-CV) booster was evaluated on Seroprotection rate 1 month postbooster. A booster dose of the Japanese encephalitis chimeric vaccine given 12-24 months after primary immunization resulted in a 100% seroprotection rate and a >50-fold increase in geometric mean titer.
Synapse has enriched 10 related papers. Consider them for comparative context: